The UK will test a cancer vaccine in a program involving thousands of patients

The man with colon cancer was the first patient in England to be treated with… Personal vaccine against the disease Within the Public Health System (NHS, in English), as reported on Friday by the UK health system.

Health authorities indicated that thousands more people are expected to arrive They were recruited to participate in vaccine trials to different forms of cancer in the coming years, according to the NHS.

The authorities described this treatment as a “historic moment” for patients and the NHS.

According to information released on Friday, the first patient received treatment Personalized colon cancer vaccine The man has been identified as Elliot Pfeiffe, a 55-year-old teacher, who was diagnosed with the disease after a routine medical examination.

After a 30-centimeter tumor was removed from his large intestine, he was transferred to Queen Elizabeth Hospital in Birmingham, central England, for a medical examination. Receiving chemotherapy Participation in a clinical trial.

“Participating in this experience is consistent with my profession as a teacher and as a community-focused person. I want Have a positive impact on life He added in statements published by the health service: “Other people and helping them develop their potential.”

He stressed, “With the potential of this test, if successful, it could help thousands, if not millions, of people, so that they have hope and do not experience everything I went through.”

the vaccine Created using mRNA technology (messenger RNA) and is jointly developed by biopharmaceutical companies BioNTech and Genentech.

According to experts, the vaccine is effective Searching for specific mutations in the tumor For the patient, doctors use the information to create personalized treatment.

See also  Amazon opens a 140,000 square meter fulfillment center in the UK

Injection is Designed to boost the immune system For the patient after surgery to remove tumors so that he can identify and attack remaining cancer cells.

Victoria Cunneen, a consultant clinical oncologist at the Queen Elizabeth Hospital in Birmingham and principal investigator on the trial, said: “Investigational cancer vaccines They are mRNA-based and are generated by tumor analysis For the patient to identify mutations specific to his or her cancer.

“Using this information we can create an individualized cancer vaccine, however It is still too early to say whether it will succeedAlthough we have a lot of hope.”

“Based on the limited data we currently have on the body’s response to the vaccine, This could be a major advance. He added: “Positive for patients, but more data is still needed and we continue to recruit suitable patients for the trial.”

Leave a Reply

Your email address will not be published. Required fields are marked *